Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors

Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacologic and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy. The s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of nuclear medicine (1978) Jg. 55; H. 10; S. 1650
Hauptverfasser: Morgat, Clément, Mishra, Anil Kumar, Varshney, Raunak, Allard, Michèle, Fernandez, Philippe, Hindié, Elif
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.10.2014
Schlagworte:
Breast Neoplasms - diagnosis
Breast Neoplasms - drug therapy
Female
Humans
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Male
Peptides - chemistry
Positron-Emission Tomography - methods
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - drug therapy
Receptors, Bombesin - chemistry
Receptors, Neuropeptide Y - chemistry
Receptors, Neurotensin - chemistry
Tomography, X-Ray Computed - methods
neurotensin
receptor
neuropeptide Y
radiopharmaceutical
cancer
molecular imaging
PET
bombesin
peptide/neuropeptide
ISSN:1535-5667, 1535-5667
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacologic and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy. The success encountered with radiolabeled somatostatin analogs is probably the first of a long list, as multiple peptide receptors are now recognized as potential targets. This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field of nuclear oncology. The underlying biology of these peptide/receptor systems, their physiologic and pathologic roles, and their differential distribution in normal and tumoral tissues are described with emphasis on breast, prostate, and lung cancers. Radiolabeled analogs that selectively target these receptors are highlighted.
AbstractList Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacologic and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy. The success encountered with radiolabeled somatostatin analogs is probably the first of a long list, as multiple peptide receptors are now recognized as potential targets. This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field of nuclear oncology. The underlying biology of these peptide/receptor systems, their physiologic and pathologic roles, and their differential distribution in normal and tumoral tissues are described with emphasis on breast, prostate, and lung cancers. Radiolabeled analogs that selectively target these receptors are highlighted.
Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacologic and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy. The success encountered with radiolabeled somatostatin analogs is probably the first of a long list, as multiple peptide receptors are now recognized as potential targets. This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field of nuclear oncology. The underlying biology of these peptide/receptor systems, their physiologic and pathologic roles, and their differential distribution in normal and tumoral tissues are described with emphasis on breast, prostate, and lung cancers. Radiolabeled analogs that selectively target these receptors are highlighted.Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these receptors and exhibit favorable pharmacologic and pharmacokinetic properties, making them suitable agents for imaging or targeted therapy. The success encountered with radiolabeled somatostatin analogs is probably the first of a long list, as multiple peptide receptors are now recognized as potential targets. This review focuses on 3 neuropeptide receptor systems (bombesin, neurotensin, and neuropeptide-Y) that offer high potential in the field of nuclear oncology. The underlying biology of these peptide/receptor systems, their physiologic and pathologic roles, and their differential distribution in normal and tumoral tissues are described with emphasis on breast, prostate, and lung cancers. Radiolabeled analogs that selectively target these receptors are highlighted.
Author Fernandez, Philippe
Hindié, Elif
Allard, Michèle
Mishra, Anil Kumar
Morgat, Clément
Varshney, Raunak
Author_xml – sequence: 1
  givenname: Clément
  surname: Morgat
  fullname: Morgat, Clément
  email: clement.morgat@chu-bordeaux.fr, elif.hindie@chu-bordeaux.fr
  organization: CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR 5287, Talence, France clement.morgat@chu-bordeaux.fr elif.hindie@chu-bordeaux.fr
– sequence: 2
  givenname: Anil Kumar
  surname: Mishra
  fullname: Mishra, Anil Kumar
  organization: University of Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR 5287, Talence, France Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, DRDO, New Delhi, India; and
– sequence: 3
  givenname: Raunak
  surname: Varshney
  fullname: Varshney, Raunak
  organization: Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, DRDO, New Delhi, India; and
– sequence: 4
  givenname: Michèle
  surname: Allard
  fullname: Allard, Michèle
  organization: CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of Bordeaux, INCIA, UMR 5287, Talence, France EPHE, Bordeaux, France
– sequence: 5
  givenname: Philippe
  surname: Fernandez
  fullname: Fernandez, Philippe
  organization: CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR 5287, Talence, France
– sequence: 6
  givenname: Elif
  surname: Hindié
  fullname: Hindié, Elif
  email: clement.morgat@chu-bordeaux.fr, elif.hindie@chu-bordeaux.fr
  organization: CHU de Bordeaux, Service de Médecine Nucléaire, Bordeaux, France University of Bordeaux, INCIA, UMR 5287, Talence, France CNRS, INCIA, UMR 5287, Talence, France clement.morgat@chu-bordeaux.fr elif.hindie@chu-bordeaux.fr
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25189338$$D View this record in MEDLINE/PubMed
BookMark eNpNkMtOwzAQRS1URB_wAWyQlyxI8St2wg5VvKRKbMqCVeQ44zZV4wQ7AfUH-G5SWkRXc0c6c6_mjtHA1Q4QuqRkylKpbteuq6CYUiqmVDBCyAka0ZjHUSylGhzpIRqHsO4BmSTJGRqymCYp58kIfS-0X0JbuiV20Pm6gaYtC8AeTK9qH7CtPTbaGfC4rPRyR2pX4HYFXjfbO9yADw2YtvyEgL_KdoXzusohlO5mb9mC-112V8cZ0ft_yjk6tXoT4OIwJ-jt8WExe47mr08vs_t5ZASJ24hZpZRNVUq4UDmjknBjpSpSmuvYyoJSntikoCnkgjIjrRDGFkpxQhXvf2cTdL33bXz90UFos6oMBjYb7aDuQkYli7ngkokevTqgXd63nDW-f99vs7_u2A8063Zp
CitedBy_id crossref_primary_10_1002_cmdc_202400843
crossref_primary_10_1631_jzus_B2300455
crossref_primary_10_3390_cancers14194922
crossref_primary_10_1053_j_semnuclmed_2025_01_001
crossref_primary_10_1016_j_phrs_2016_04_018
crossref_primary_10_1021_acs_jmedchem_8b00435
crossref_primary_10_1007_s11033_020_05532_1
crossref_primary_10_1016_j_apsusc_2018_12_158
crossref_primary_10_1007_s00428_017_2215_y
crossref_primary_10_1007_s10549_021_06402_5
crossref_primary_10_1016_j_ijpharm_2015_12_069
crossref_primary_10_1089_ten_tea_2017_0158
crossref_primary_10_1371_journal_pone_0210905
crossref_primary_10_3390_app12188990
crossref_primary_10_1016_j_semradonc_2020_07_010
crossref_primary_10_3892_etm_2019_7998
crossref_primary_10_1016_j_apsusc_2017_11_100
crossref_primary_10_1002_psc_2753
crossref_primary_10_1016_j_cclet_2023_108672
crossref_primary_10_1186_s12951_025_03303_3
crossref_primary_10_3389_fmed_2022_812050
crossref_primary_10_1007_s00259_016_3319_3
crossref_primary_10_1186_s13550_020_0612_8
crossref_primary_10_1016_j_mednuc_2017_07_007
crossref_primary_10_3390_molecules24010049
crossref_primary_10_1002_ijc_31793
crossref_primary_10_1007_s00223_017_0352_6
crossref_primary_10_1016_j_ejmech_2021_113538
crossref_primary_10_3390_pharmaceutics13081160
crossref_primary_10_1021_acs_jmedchem_6b00043
crossref_primary_10_1007_s00259_019_04355_y
crossref_primary_10_1016_j_peptides_2016_07_004
crossref_primary_10_1080_2162402X_2018_1440166
crossref_primary_10_2967_jnumed_124_269444
crossref_primary_10_1007_s00259_023_06142_2
crossref_primary_10_1002_cmdc_201402514
crossref_primary_10_3390_ijms20071721
crossref_primary_10_1259_bjr_20150042
crossref_primary_10_1039_C6MD00131A
crossref_primary_10_3390_pharmaceutics15061733
crossref_primary_10_1038_nchembio_1907
crossref_primary_10_1016_j_phanu_2020_100191
crossref_primary_10_1007_s00216_016_0119_3
crossref_primary_10_1016_j_saa_2019_02_051
crossref_primary_10_1097_RLU_0000000000002672
crossref_primary_10_1002_open_201700191
crossref_primary_10_1007_s11307_019_01318_5
crossref_primary_10_1002_slct_201601960
crossref_primary_10_1016_j_addr_2016_06_007
crossref_primary_10_2967_jnumed_115_170530
crossref_primary_10_1016_j_peptides_2015_04_026
crossref_primary_10_1515_ract_2019_0004
crossref_primary_10_3390_ijms18020260
crossref_primary_10_1016_j_biomaterials_2016_11_028
crossref_primary_10_1016_j_biopha_2025_118117
crossref_primary_10_3389_fchem_2022_830133
crossref_primary_10_1186_s13550_019_0517_6
crossref_primary_10_3389_fchem_2020_583309
crossref_primary_10_1002_jlcr_3581
crossref_primary_10_3390_ijms18081639
crossref_primary_10_3390_ph10010029
crossref_primary_10_1016_j_mednuc_2018_08_003
crossref_primary_10_1038_s41598_022_05949_7
ContentType Journal Article
Copyright 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Copyright_xml – notice: 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.2967/jnumed.114.142000
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1535-5667
ExternalDocumentID 25189338
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
-~X
.55
.GJ
29L
2WC
3O-
41~
53G
5RE
7RV
7X7
88E
88I
8AF
8AO
8FE
8FG
8FH
8FI
8FJ
8R4
8R5
8WZ
A6W
ABEFU
ABSQV
ABUWG
ACGOD
ACIWK
ACPRK
ADDZX
ADMOG
AENEX
AFFNX
AFKRA
AFOSN
AFRAH
AHMBA
AI.
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
DWQXO
E3Z
EBD
EBS
ECM
EIF
EJD
EMOBN
EX3
F5P
F9R
FYUFA
GNUQQ
H13
HCIFZ
HMCUK
I-F
IL9
INIJC
J5H
KQ8
L7B
LK8
M1P
M2P
M2Q
M7P
N4W
NAPCQ
NPM
OK1
P2P
P62
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
Q2X
R0Z
RHI
RNS
RWL
S0X
SJN
SV3
TAE
TR2
TSM
TUS
UKHRP
VH1
W8F
WH7
WOQ
WOW
X7M
YHG
YQJ
ZGI
ZXP
7X8
ID FETCH-LOGICAL-c405t-2f777f9790347b21603cf67d91ba5f6d1138f8d19eb412c6f44cfd77301736882
IEDL.DBID 7X8
ISICitedReferencesCount 87
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000342712600024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1535-5667
IngestDate Fri Sep 05 11:16:32 EDT 2025
Mon Jul 21 05:39:58 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords neurotensin
receptor
neuropeptide Y
radiopharmaceutical
cancer
molecular imaging
PET
bombesin
peptide/neuropeptide
Language English
License 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c405t-2f777f9790347b21603cf67d91ba5f6d1138f8d19eb412c6f44cfd77301736882
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink http://jnm.snmjournals.org/content/55/10/1650.full.pdf
PMID 25189338
PQID 1625343624
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1625343624
pubmed_primary_25189338
PublicationCentury 2000
PublicationDate 2014-Oct
20141001
PublicationDateYYYYMMDD 2014-10-01
PublicationDate_xml – month: 10
  year: 2014
  text: 2014-Oct
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of nuclear medicine (1978)
PublicationTitleAlternate J Nucl Med
PublicationYear 2014
SSID ssj0006888
Score 2.4444947
SecondaryResourceType review_article
Snippet Receptors for some regulatory peptides are highly expressed in tumors. Selective radiolabeled peptides can bind with high affinity and specificity to these...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 1650
SubjectTerms Breast Neoplasms - diagnosis
Breast Neoplasms - drug therapy
Female
Humans
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Male
Peptides - chemistry
Positron-Emission Tomography - methods
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - drug therapy
Receptors, Bombesin - chemistry
Receptors, Neuropeptide Y - chemistry
Receptors, Neurotensin - chemistry
Tomography, X-Ray Computed - methods
Title Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors
URI https://www.ncbi.nlm.nih.gov/pubmed/25189338
https://www.proquest.com/docview/1625343624
Volume 55
WOSCitedRecordID wos000342712600024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPBo2G2TNq0XEXHx4C57WGU9leYFu7Bt3a6Cf8Df7STtUi-C4KWkhyQlmZl8nZnMh9AV0zrqqgA0LXTeKhYSATaQCKoDJjgzwnEsvTzxwSAaj-Nh7XAr67TKpU10hlrl0vrIOx4AdcrA3LLb4o1Y1igbXa0pNFZRiwKUsVLNx0218DByvJOg1AEB2MKrqKYfh7wzzUD1la2UC7bCXlf5HWG6k6a3_d9v3EFbNcbEd5VQ7KIVne2hjX4dRd9HXyOX_g2HFnblLAub2aI0BuMHrXxeYkCyWFp5mOPJzPEY4TRTuLqs9XmDi-aKZomtKxeLfGYpBrLrakiXFw8vttfPOchrM8sBeu49jO4fSc3HQCTAugXxDefcxDzuUsaFbwmqpQm5ij2RBiZUnkcjEykv1oJ5vgwNY9Iobm0Ip7AX_iFay_JMHyMsWRoE8K-nUpECIIMBFA88aqgWRom020aXyxVOQN5tECPNdP5eJs0at9FRtU1JURXmSACrAfyi0ckfep-iTcA-rMrLO0MtA9quz9G6_FhMyvmFEyR4Dob9b2nO1Yo
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+neuropeptide+receptors+for+cancer+imaging+and+therapy%3A+perspectives+with+bombesin%2C+neurotensin%2C+and+neuropeptide-Y+receptors&rft.jtitle=The+Journal+of+nuclear+medicine+%281978%29&rft.au=Morgat%2C+Cl%C3%A9ment&rft.au=Mishra%2C+Anil+Kumar&rft.au=Varshney%2C+Raunak&rft.au=Allard%2C+Mich%C3%A8le&rft.date=2014-10-01&rft.eissn=1535-5667&rft.volume=55&rft.issue=10&rft.spage=1650&rft_id=info:doi/10.2967%2Fjnumed.114.142000&rft_id=info%3Apmid%2F25189338&rft_id=info%3Apmid%2F25189338&rft.externalDocID=25189338
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-5667&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-5667&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-5667&client=summon